NCT04285671View on ClinicalTrials.gov

Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 29, 2021

Primary Completion Date

December 2, 2025

Study Completion Date

December 2, 2026

Conditions
Metastatic Lung Non-Small Cell CarcinomaRefractory Lung Non-Small Cell CarcinomaStage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8Stage IVA Lung Cancer AJCC v8Stage IVB Lung Cancer AJCC v8
Interventions
BIOLOGICAL

Necitumumab

Given IV

DRUG

Osimertinib

Given PO

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

BIOLOGICAL

Trastuzumab

Given IV

Trial Locations (1)

90095

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

lead

Jonsson Comprehensive Cancer Center

OTHER

NCT04285671 - Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter